Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-world data on multiple myeloma immunotherapies could reshape monitoring and improve survival

NCT ID NCT06855121

Knowledge-focused Sponsor: St. Olavs Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This study follows 400 people in Norway with multiple myeloma, plasma cell leukemia, or AL amyloidosis who are receiving newer immunotherapies like teclistamab, elranatamab, or CAR-T cell therapy outside of clinical trials. Researchers will track how well these treatments control the cancer and what side effects occur, including infections and neurological issues. The goal is to fill knowledge gaps and develop better ways to monitor and manage side effects in everyday practice.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
teclistamab, elranatamab, ciltacabtagene autoleucel, talquetamab, idecabtagene vicleucel
What this could lead to
If successful, this study could help doctors better manage side effects and improve survival and quality of life for people with multiple myeloma.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may vary across different patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2025

Expected to finish

Dec 2037

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with multiple myeloma, plasma cell leukemia or AL amyloidosis treated at study sites outside clinical trials.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria * Participants age ≥ 18 years * Prior diagnosis of one of the following * Multiple myeloma as defined according to IMWG criteria * Primary plasma cell leukemia as defined according to IMWG consensus definition * AL-amyloidosis as defined according to IMWG criteria * Planned treatment with one of the following outside clinical trials (list to be amended based on approvals within the EU): * Teclistamab (Tecvayli) * Elranatamab (Elrexfio) * Talquetamab (Talvey) * Idecabtagene vicleucel (ide-cel/Abecma) * Ciltacabtagene autoleucel (cilta-cel/Carvykti) Exclusion Criteria: * None

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Al amyloidosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AL amyloidosis Immunoglobulin Light-chain Amyloidosis Infections plasma cell leukemia plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Al amyloidosis Myeloma multiple Plasma cell leukemia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    23 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Akershus University Hospital (AHUS)

    NOT_YET_RECRUITING

    Nordbyhagen, Norway

  • Bodø Hospital

    NOT_YET_RECRUITING

    Bodø, Norway

  • Bærum Hospital

    NOT_YET_RECRUITING

    Bærum, Norway

  • Diakonhjemmet hospital

    NOT_YET_RECRUITING

    Oslo, Norway

  • Drammen hospital

    NOT_YET_RECRUITING

    Drammen, Norway

  • Førde hospital

    NOT_YET_RECRUITING

    Førde, Norway

  • Haugesund hospital

    NOT_YET_RECRUITING

    Haugesund, Norway

  • Haukeland University Hospital

    NOT_YET_RECRUITING

    Bergen, Norway

  • Innlandet hospital trust

    NOT_YET_RECRUITING

    Gjøvik, Norway

  • Levanger hospital

    NOT_YET_RECRUITING

    Levanger, Norway

  • Lovisenberg Diaconal Hospital

    NOT_YET_RECRUITING

    Oslo, Norway

  • Nordmøre and Romsdal Hospital - Kristiansund

    NOT_YET_RECRUITING

    Kristiansund, Norway

  • Nordmøre and Romsdal Hospital - Molde

    NOT_YET_RECRUITING

    Molde, Norway

  • Oslo Myeloma Center, Oslo University Hospital

    NOT_YET_RECRUITING

    Oslo, Norway

  • St. Olavs hospital HF

    RECRUITING

    Trondheim, Norway

  • Stavanger University hospital

    NOT_YET_RECRUITING

    Stavanger, Norway

  • Sørlandet Hospital - Arendal

    NOT_YET_RECRUITING

    Arendal, Norway

  • Sørlandet hospital

    NOT_YET_RECRUITING

    Kristiansand, Norway

  • Telemark Hospital Trust

    NOT_YET_RECRUITING

    Skien, Norway

  • University hospital of North Norway

    NOT_YET_RECRUITING

    Tromsø, Norway

  • Vestfold Hospital Trust

    NOT_YET_RECRUITING

    Tønsberg, Norway

  • Volda hospital

    NOT_YET_RECRUITING

    Volda, Norway

  • Ålesund hospital, Department of hematology

    NOT_YET_RECRUITING

    Ålesund, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.